

REFERENCES

Jump to Section

- [Top](#)
- [Introduction](#)
- [Epidemiology](#)
- [Pathophysiology of diabetic...](#)
- [Medical treatment](#)
- [Conclusion](#)
- [Author information](#)
- [References](#)

1. Resnick HE, Shorr RI, Kuller L, et al. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults. *J Clin Epidemiol.* 2001;54:869-876. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
2. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. *J Clin Epidemiol.* 1992;45:1327-1334. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
3. Haffner SM, Lehto S, Ronnema T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 1998;339:229-234. [FREE FULL TEXT](#)
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA.* 2001;285:2486-2497. [FREE FULL TEXT](#)
5. Kjaergaard SC, Hansen HH, Fog L, et al. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. *Scand Cardiovasc J.* 1999;33:166-170. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
6. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation.* 2000;102:1014-1019. [FREE FULL TEXT](#)
7. Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction. *J Am Coll Cardiol.* 1993;22:1788-1794. [ABSTRACT](#)

8. Shindler DM, Palmeri ST, Antonelli TA, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction. *J Am Coll Cardiol*. 2000;36:1097-1103. [FREE FULL TEXT](#)
9. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. *Diabetes Care*. 1998;21:69-75. [ABSTRACT](#)
10. Herlitz J, Karlson BW, Lindqvist J, Sjolín M. Rate and mode of death during five years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. *Diabet Med*. 1998;15:308-314. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
11. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. *Circulation*. 1993;88:837-845. [ISI](#) | [PUBMED](#)
12. Abbott RD, Brand FN, Kannel WB. Epidemiology of some peripheral arterial findings in diabetic men and women. *Am J Med*. 1990;88:376-381. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
13. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. *Arterioscler Thromb Vasc Biol*. 1998;18:185-192. [FREE FULL TEXT](#)
14. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. *Circulation*. 1995;91:1472-1479. [ISI](#) | [PUBMED](#)
15. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients. *Diabetes Care*. 2001;24:1433-1437. [FREE FULL TEXT](#)
16. Beks PJ, Mackaay AJ, de Neeling JN, et al. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. *Diabetologia*. 1995;38:86-96. [ISI](#) | [PUBMED](#)
17. Uusitupa MI, Niskanen LK, Siitonen O, et al. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. *Circulation*. 1990;82:27-36. [ISI](#) | [PUBMED](#)

18. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. *J Am Geriatr Soc.* 1985;33:13-18. [ISI](#) | [PUBMED](#)
19. Diabetes-related amputations of lower extremities in the Medicare population—Minnesota, 1993-1995. *MMWR Morb Mortal Wkly Rep.* 1998;47:649-652. [PUBMED](#)
20. Fabris F, Zanocchi M, Bo M, et al. Carotid plaque, aging, and risk factors. *Stroke.* 1994;25:1133-1140. [ABSTRACT](#)
21. Friedlander AH, Maeder LA. The prevalence of calcified carotid artery atheromas on the panoramic radiographs of patients with type 2 diabetes mellitus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2000;89:420-424. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
22. Himmelmann A, Hansson L, Svensson A, et al. Predictors of stroke in the elderly. *Acta Med Scand.* 1988;224:439-443. [ISI](#) | [PUBMED](#)
23. Jamrozik K, Broadhurst RJ, Forbes S, et al. Predictors of death and vascular events in the elderly. *Stroke.* 2000;31:863-868. [FREE FULL TEXT](#)
24. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. *Diabetes Care.* 1999;22:1077-1083. [FREE FULL TEXT](#)
25. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. *Stroke.* 1994;25:1157-1164. [ABSTRACT](#)
26. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care.* 1993;16:434-444. [ABSTRACT](#)
27. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes: the Copenhagen Stroke Study. *Stroke.* 1994;25:1977-1984. [ABSTRACT](#)
28. You RX, McNeil JJ, O'Malley HM, et al. Risk factors for stroke due to cerebral infarction in young adults. *Stroke.* 1997;28:1913-1918. [FREE FULL TEXT](#)

29. Rohr J, Kittner S, Feeser B, et al. Traditional risk factors and ischemic stroke in young adults. *Arch Neurol*. 1996;53:603-607. [ABSTRACT](#)

30. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol*. 2001;154:635-641. [FREE FULL TEXT](#)

31. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. *Stroke*. 1998;29:2491-2500. [FREE FULL TEXT](#)

32. Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke. *Stroke*. 1996;27:210-215. [FREE FULL TEXT](#)

33. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. *Arch Intern Med*. 2001;161:1717-1723. [FREE FULL TEXT](#)

34. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. *Diabetologia*. 1995;38:1061-1068. [ISI](#) | [PUBMED](#)

35. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. *JAMA*. 1999;281:1291-1297. [FREE FULL TEXT](#)

36. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. *Blood*. 1998;91:3527-3561. [FREE FULL TEXT](#)

37. Verma S, Anderson TJ. The ten most commonly asked questions about endothelial function in cardiology. *Cardiol Rev*. 2001;9:250-252. [FULL TEXT](#) | [PUBMED](#)

38. Sarkar R, Meinberg EG, Stanley JC, et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. *Circ Res*. 1996;78:225-230. [FREE FULL TEXT](#)

39. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A*. 1991;88:4651-4655. [FREE FULL TEXT](#)

40. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol*. 1996;27:567-574. [ABSTRACT](#)
41. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. *Circulation*. 1993;88:2510-2516. [ISI](#) | [PUBMED](#)
42. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. *Br J Pharmacol*. 2000;130:963-974. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
43. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite. *Biochem Biophys Res Commun*. 1999;263:681-684. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
44. Hennes MM, O'Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. *Hypertension*. 1996;28:120-126. [FREE FULL TEXT](#)
45. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes*. 2000;49:1939-1945. [ABSTRACT](#)
46. Zou M, Yesilkaya A, Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. *Drug Metab Rev*. 1999;31:343-349. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
47. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. *Diabetologia*. 1999;42:1383-1394. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
48. Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. *Diabetes*. 2000;49:1561-1570. [ABSTRACT](#)
49. Achmad TH, Winterscheidt A, Lindemann C, Rao GS. Oxidized low density lipoprotein acts on endothelial cells in culture to enhance endothelin secretion and monocyte migration. *Methods Find Exp Clin Pharmacol*. 1997;19:153-159. [ISI](#) | [PUBMED](#)

50. Xie H, Bevan JA. Oxidized low-density lipoprotein enhances myogenic tone in the rabbit posterior cerebral artery through the release of endothelin-1. *Stroke*. 1999;30:2423-2429. [FREE FULL TEXT](#)

51. Christlieb AR, Janka HU, Kraus B, et al. Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects. *Diabetes*. 1976;25:268-274. [ABSTRACT](#)

52. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. *J Clin Invest*. 1990;85:929-932. [ISI](#) | [PUBMED](#)

53. Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. *Drugs*. 1998;56(suppl 1):9-13.

54. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation*. 2001;104:365-372. [FREE FULL TEXT](#)

55. Schmidt AM, Stern D. Atherosclerosis and diabetes. *Curr Atheroscler Rep*. 2000;2:430-436. [PUBMED](#)

56. Rosen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications. *Diabetes Metab Res Rev*. 2001;17:189-212. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

57. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. *Circ Res*. 1995;76:980-986. [FREE FULL TEXT](#)

58. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. *Circ Res*. 1999;84:1085-1094. [FREE FULL TEXT](#)

59. Hussain MJ, Peakman M, Gallati H, et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. *Diabetologia*. 1996;39:60-69. [ISI](#) | [PUBMED](#)

60. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity. *Circ Res*. 2001;88:1291-1298. [FREE FULL TEXT](#)

61. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. *Arterioscler Thromb Vasc Biol.* 1995;15:1114-1120. [FREE FULL TEXT](#)

62. Nugent AG, McGurk C, Hayes JR, Johnston GD. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. *Diabetes.* 1996;45:105-107. [ABSTRACT](#)

63. Tesfamariam B, Cohen RA. Enhanced adrenergic neurotransmission in diabetic rabbit carotid artery. *Cardiovasc Res.* 1995;29:549-554. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

64. McDaid EA, Monaghan B, Parker AI, et al. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. *Diabetes Care.* 1994;17:1422-1427. [ABSTRACT](#)

65. Takahashi T, Nishizawa Y, Emoto M, et al. Sympathetic function test of vasoconstrictor changes in foot arteries in diabetic patients. *Diabetes Care.* 1998;21:1495-1501. [ABSTRACT](#)

66. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis. *Diabetes.* 2001;50:851-860. [FREE FULL TEXT](#)

67. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. *J Atheroscler Thromb.* 1998;5:29-35. [PUBMED](#)

68. Taguchi S, Oinuma T, Yamada T. A comparative study of cultured smooth muscle cell proliferation and injury, utilizing glycated low density lipoproteins with slight oxidation, auto-oxidation, or extensive oxidation. *J Atheroscler Thromb.* 2000;7:132-137. [PUBMED](#)

69. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. *Diabetes Care.* 2001;24:1476-1485. [FREE FULL TEXT](#)

70. Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. *Diabetologia.* 2001;44:188-195. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

71. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. *Am J Physiol Heart Circ Physiol*. 2001;280:H1480-H1489.
72. Carr ME. Diabetes mellitus: a hypercoagulable state. *J Diabetes Complications*. 2001;15:44-54. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
73. Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. *Diabetologia*. 1988;31:889-891. [ISI](#) | [PUBMED](#)
74. Ceriello A, Giugliano D, Quatraro A, et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. *Diabetologia*. 1990;33:163-167. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
75. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. *Diabetes*. 1995;44:924-928. [ABSTRACT](#)
76. Nordt TK, Bode C. Impaired endogenous fibrinolysis in diabetes mellitus. *Semin Thromb Hemost*. 2000;26:495-501. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
77. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
78. Turner RC. The U.K. Prospective Diabetes Study: a review. *Diabetes Care*. 1998;21(suppl 3):C35-C38.
79. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. *Diabetes Care*. 1999;22:233-240. [FREE FULL TEXT](#)
80. Bavenholm P, Proudler A, Tornvall P, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. *Circulation*. 1995;92:1422-1429. [ISI](#) | [PUBMED](#)
81. Adachi H, Hirai Y, Tsuruta M, et al. Is insulin resistance or diabetes mellitus associated with stroke? *Diabetes Res Clin Pract*. 2001;51:215-223. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

82. Schaper NC, Nabuurs-Franssen MH, Huijberts MS. Peripheral vascular disease and type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2000;16(suppl 1):S11-S15.

83. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352:854-865. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

84. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. *Diabetes Care*. 2000;23:1605-1611. [FREE FULL TEXT](#)

85. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis. *Curr Atheroscler Rep*. 2000;2:327-335. [PUBMED](#)

86. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. *Am J Pathol*. 1998;153:17-23. [FREE FULL TEXT](#)

87. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. *J Clin Invest*. 1994;94:2349-2356. [ISI](#) | [PUBMED](#)

88. Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. *Diabetologia*. 1995;38:959-967. [ISI](#) | [PUBMED](#)

89. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. *Ann Intern Med*. 2001;135:447-459. [FREE FULL TEXT](#)

90. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. *Am J Cardiol*. 1995;75:1196-1201. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

91. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. *Arterioscler Thromb Vasc Biol*. 1999;19:2226-2233. [FREE FULL TEXT](#)

92. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. *J Clin Invest.* 1993;92:141-146. [ISI](#) | [PUBMED](#)
93. Tan KC, Cooper MB, Ling KL, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia. *Atherosclerosis.* 1995;113:273-287. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
94. Sniderman A, Thomas D, Marpole D, Teng B. Low density lipoprotein: a metabolic pathway for return of cholesterol to the splanchnic bed. *J Clin Invest.* 1978;61:867-873. [ISI](#) | [PUBMED](#)
95. Dimitriadis E, Griffin M, Owens D, et al. Oxidation of low-density lipoprotein in NIDDM. *Diabetologia.* 1995;38:1300-1306. [ISI](#) | [PUBMED](#)
96. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. *Curr Opin Lipidol.* 1998;9:471-474. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
97. Malmstrom R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. *Diabetologia.* 1997;40:454-462. [FULL TEXT](#) | [PUBMED](#)
98. Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. *Diabetes Care.* 2001;24:1590-1595. [FREE FULL TEXT](#)
99. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. *Circulation.* 1998;98:2513-2519. [ISI](#) | [PUBMED](#)
100. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. *Diabetes Care.* 1997;20:614-620. [ABSTRACT](#)
101. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. *Atherosclerosis.* 1998;141:203-207. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

102. Collins R. *Heart Protection Study*. Oxford, England: Oxford University Press; 2001.
103. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. *N Engl J Med*. 1999;341:410-418. [FREE FULL TEXT](#)
104. Marx N, Sukhova GK, Collins T, et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. *Circulation*. 1999;99:3125-3131. [ISI](#) | [PUBMED](#)
105. Marx N, Mackman N, Schonbeck U, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. *Circulation*. 2001;103:213-219. [ISI](#) | [PUBMED](#)
106. Elam MB, Hunninghake DB, Davis KB, et al for the ADMIT investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. *JAMA*. 2000;284:1263-1270. [FREE FULL TEXT](#)
107. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. *Diabetes Care*. 1998;21:796-799. [ABSTRACT](#)
108. Cominacini L, Young MM, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. *Diabetologia*. 1997;40:1211-1218. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
109. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. *Ann Intern Med*. 2001;134:61-71. [FREE FULL TEXT](#)
110. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. *Hypertension*. 2001;37:1053-1059. [FREE FULL TEXT](#)
111. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *N Engl J Med*. 1999;340:677-684. [FREE FULL TEXT](#)

112. Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. *Lancet*. 1998;351:1755-1762. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

113. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703-713. [FREE FULL TEXT](#)

114. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ*. 1998;317:713-720. [FREE FULL TEXT](#)

115. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*. 2000;355:253-259. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

116. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:1004-1010. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

117. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care*. 1998;21:597-603. [ABSTRACT](#)

118. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ*. 1994;308:81-106. [FREE FULL TEXT](#)

119. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med*. 1997;337:447-452. [FREE FULL TEXT](#)

120. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. *N Engl J Med*. 1998;338:1488-1497. [FREE FULL TEXT](#)

121. Ramanathan AV, Miller DP, Kleiman NS. Effect of GP IIb/IIIa antagonists in patients with diabetes mellitus. *Circulation*. 1999;100:I-640.
122. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents: the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. *J Am Coll Cardiol*. 1993;21:920-925. [ABSTRACT](#)
123. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction: GUSTO-I Investigators. *J Am Coll Cardiol*. 1997;30:171-179. [ABSTRACT](#)
124. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction. *Lancet*. 1994;343:311-322. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
125. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. *Ann Intern Med*. 1995;123:358-367. [FREE FULL TEXT](#)
126. Chen J, Marciniak TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. *J Am Coll Cardiol*. 1999;34:1388-1394. [FREE FULL TEXT](#)
127. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. *Circulation*. 1995;91:979-989. [ISI](#) | [PUBMED](#)
128. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. *J Am Coll Cardiol*. 1998;32:1866-1873. [FREE FULL TEXT](#)
129. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *Circulation*. 1996;94:1818-1825. [ISI](#) | [PUBMED](#)
130. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. *Ann Intern Med*. 1993;118:344-349. [FREE FULL TEXT](#)

131. Levine GN, Jacobs AK, Keeler GP, et al for the CAVEAT-I Investigators. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). *Am J Cardiol.* 1997;79:748-755. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
132. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. *J Am Coll Cardiol.* 1998;32:584-589. [FREE FULL TEXT](#)
133. Moreno PR, Fallon JT, Murcia AM, et al. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. *J Am Coll Cardiol.* 1999;34:1045-1049. [FREE FULL TEXT](#)
134. Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. *N Engl J Med.* 2000;342:989-997. [FREE FULL TEXT](#)
135. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med.* 1996;335:217-225. [FREE FULL TEXT](#)
136. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. *Circulation.* 1997;96:1761-1769. [PUBMED](#)
137. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol.* 1998;81:333-335. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
138. Sumpio BE. Foot ulcers. *N Engl J Med.* 2000;343:787-793. [FREE FULL TEXT](#)
139. LoGerfo FW, Coffman JD. Current concepts: vascular and microvascular disease of the foot in diabetes. *N Engl J Med.* 1984;311:1615-1619. [ISI](#) | [PUBMED](#)
140. Peters EJ, Lavery LA. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. *Diabetes Care.* 2001;24:1442-1447. [FREE FULL TEXT](#)

141. Jirkovska A, Boucek P, Woskova V, et al. Identification of patients at risk for diabetic foot. *J Diabetes Complications*. 2001;15:63-68. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

142. Dahmen R, Haspels R, Koomen B, Hoeksma AF. Therapeutic footwear for the neuropathic foot. *Diabetes Care*. 2001;24:705-709. [FREE FULL TEXT](#)

143. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. *JAMA*. 1995;274:975-980. [ABSTRACT](#)

144. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group. *J Vasc Surg*. 2000;31:S1-S296.

145. Lewis TV, Dart AM, Chin-Dusting JP, Kingwell BA. Exercise training increases basal nitric oxide production from the forearm in hypercholesterolemic patients. *Arterioscler Thromb Vasc Biol*. 1999;19:2782-2787. [FREE FULL TEXT](#)

146. Hiatt WR, Regensteiner JG, Wolfel EE, et al. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. *J Appl Physiol*. 1996;81:780-788. [FREE FULL TEXT](#)

147. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. *Thromb Haemost*. 1999;82:435-438. [ISI](#) | [PUBMED](#)

148. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. *Arterioscler Thromb Vasc Biol*. 1998;18:1942-1947. [FREE FULL TEXT](#)

149. Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. *Am J Cardiol*. 2001;87:19D-27D.

150. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication. *Circulation*. 1998;98:678-686. [ISI](#) | [PUBMED](#)

151. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. *Gen Pharmacol*. 1997;29:181-196. [ISI](#) | [PUBMED](#)

152. Hiatt WR. Current and future drug therapies for claudication. *Vasc Med.* 1997;2:257-262. [PUBMED](#)

153. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: factors influencing long-term success. *Circulation.* 1991;83(suppl 2):I70-I80.

154. Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. *Ann Surg.* 1987;206:403-413. [ISI](#) | [PUBMED](#)

155. Stokes KR, Strunk HM, Campbell DR, et al. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. *Radiology.* 1990;174:977-982. [ABSTRACT](#)

156. Panneton JM, Gloviczki P, Bower TC, et al. Pedal bypass for limb salvage: impact of diabetes on long-term outcome. *Ann Vasc Surg.* 2000;14:640-647. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

157. Faries PL, LoGerfo FW, Hook SC, et al. The impact of diabetes on arterial reconstructions for multilevel arterial occlusive disease. *Am J Surg.* 2001;181:251-255. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

158. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA.* 1995;273:1421-1428. [ABSTRACT](#)

159. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med.* 1991;325:445-453. [ABSTRACT](#)

160. Ahari A, Bergqvist D, Troeng T, et al. Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 1999;18:122-126. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

161. Aziz I, Lewis RJ, Baker JD, Virgilio C. Cardiac morbidity and mortality following carotid endarterectomy. *Ann Vasc Surg.* 2001;15:243-246. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

162. Pistolese GR, Appolloni A, Ronchey S, Martelli E. Carotid endarterectomy in diabetic patients. *J Vasc Surg.* 2001;33:148-154. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

163. Akbari CM, Pomposelli FB Jr, Gibbons GW, et al. Diabetes mellitus: a risk factor for carotid endarterectomy? *J Vasc Surg.* 1997;25:1070-1075. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

164. Roubin GS, New G, Iyer SS, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis. *Circulation.* 2001;103:532-537. [ISI](#) | [PUBMED](#)

165. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. *JAMA.* 2001;285:1711-1718. [FREE FULL TEXT](#)

166. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med.* 2001;134:629-636. [FREE FULL TEXT](#)

167. Early Treatment Diabetic Retinopathy Study report 14. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. *JAMA.* 1992;268:1292-1300. [ABSTRACT](#)

168. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. *Circulation.* 2001;104:2767-2771. [FREE FULL TEXT](#)